Zhengye Biotechnology Holding Limited Accounts Payable

The latest accounts payable for ZYBT is $44M as of December 2025. That compares with $43M in the prior-year period — up 2.4% year over year. Investors often review this figure alongside Zhengye Biotechnology Holding Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZYBT's accounts payable moved from $43M to $44M — a 2.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zhengye Biotechnology Holding Limited's operating scale or balance-sheet position.

A accounts payable figure of $44M for ZYBT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ZYBT's accounts payable ($44M), review year-over-year change from $43M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.